← Back to catalogue

Dexcom G5 Mobile Continuous Glucose Monitoring System

FDA PMA

Class III (US FDA PMA)

PMA P120005

by Dexcom, Inc.

Identity

Trade Name
DEXCOM G4 PLATINUM CONTIUOUS GLUCOSE MONITORING SYSTEM FDA PMA
Generic Name
Sensor, glucose, invasive FDA PMA

Identifiers

PMA Number
P120005 FDA PMA
FDA Product Code
MDS FDA PMA

Classification

Device Class
Class III FDA PMA
Advisory Committee
Clinical Chemistry FDA PMA
FDA Decision
APWD FDA PMA

The Dexcom G5 Mobile Continuous Glucose Monitoring System is a glucose sensor, invasive, designed for detecting glucose trends and tracking patterns in individuals aged 18 and older with diabetes. This system provides real-time glucose monitoring via an implanted sensor, enabling continuous assessment of blood glucose levels without frequent fingerstick tests.

Intended for single-patient use and requiring a prescription, the system operates as an adjunct to standard home glucose monitoring devices. It aids in identifying episodes of hyperglycemia and hypoglycemia, supporting acute and long-term therapy adjustments. The device is approved for FDA_PMA under PMA number P120005 and is classified as a Class III medical device. Supplied as a reusable transmitter paired with single-use sensors, it is not MRI-safe and must be stored according to manufacturer guidelines.

This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them. Sources consulted: Dexcom Continuous Glucose Monitoring | Dexcom CGM | Dexcom, Dexcom – Wikipedia, Dexcom CGM-Systeme | DIASHOP, Die Alternative zum Fingerstich*: Dexcom Flex | Dexcom

Authorization Coverage (1 country)

Regulatory Authorizations

United States Active

FDA_PMA

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Dexcom, Inc.

Sources (1)

  • FDA PMA P120005 24 fields · synced Sep 18, 2026